JP2017501148A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501148A5
JP2017501148A5 JP2016538783A JP2016538783A JP2017501148A5 JP 2017501148 A5 JP2017501148 A5 JP 2017501148A5 JP 2016538783 A JP2016538783 A JP 2016538783A JP 2016538783 A JP2016538783 A JP 2016538783A JP 2017501148 A5 JP2017501148 A5 JP 2017501148A5
Authority
JP
Japan
Prior art keywords
protein
mixture
conjugation
chemical moiety
reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016538783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501148A (ja
JP6603662B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077777 external-priority patent/WO2015086853A1/en
Publication of JP2017501148A publication Critical patent/JP2017501148A/ja
Publication of JP2017501148A5 publication Critical patent/JP2017501148A5/ja
Application granted granted Critical
Publication of JP6603662B2 publication Critical patent/JP6603662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016538783A 2013-12-13 2014-12-15 タンパク質のチオエーテルコンジュゲーション方法 Active JP6603662B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13197150.9 2013-12-13
EP13197150 2013-12-13
PCT/EP2014/077777 WO2015086853A1 (en) 2013-12-13 2014-12-15 Method for thioether conjugation of proteins

Publications (3)

Publication Number Publication Date
JP2017501148A JP2017501148A (ja) 2017-01-12
JP2017501148A5 true JP2017501148A5 (OSRAM) 2018-01-25
JP6603662B2 JP6603662B2 (ja) 2019-11-06

Family

ID=49765887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538783A Active JP6603662B2 (ja) 2013-12-13 2014-12-15 タンパク質のチオエーテルコンジュゲーション方法

Country Status (6)

Country Link
US (1) US11219690B2 (OSRAM)
EP (1) EP3079722B1 (OSRAM)
JP (1) JP6603662B2 (OSRAM)
CN (1) CN106068127B (OSRAM)
ES (1) ES2869309T3 (OSRAM)
WO (1) WO2015086853A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY197023A (en) 2015-12-23 2023-05-22 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
MX2019013919A (es) 2017-06-20 2020-01-21 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
EP3642238A1 (en) 2017-06-21 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
AU2018309090B2 (en) * 2017-08-04 2023-03-30 Amgen Inc. Method of conjugation of cys-mAbs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
NZ513077A (en) * 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2004101597A2 (en) 2003-05-13 2004-11-25 Frutarom Ltd. Methods for the reduction of disulfide bonds
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
US20090062509A1 (en) * 2006-03-16 2009-03-05 Aldo Cagnolini Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
US8586532B2 (en) 2007-08-24 2013-11-19 Novo Nordisk Healthcare A/G Method for selectively modifying a protein via transglutaminase catalyzed reaction
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
SI2525834T1 (sl) * 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
US20130012684A1 (en) 2010-02-16 2013-01-10 Novo Nordisk A/S Purification Method
WO2012010516A1 (en) 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Growth hormone conjugates
EP3412314A1 (en) 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
SI2773438T2 (sl) * 2011-11-02 2022-05-31 F.Hoffmann-La Roche Ag Izpiralna kromatografija s preobremenitvijo
CN103087183A (zh) 2013-01-17 2013-05-08 南京邮电大学 一种光激发蛋白质中二硫键还原得到自由巯基的方法

Similar Documents

Publication Publication Date Title
JP2017501148A5 (OSRAM)
Leichner et al. Thiolated polymers: Bioinspired polymers utilizing one of the most important bridging structures in nature
KR102843708B1 (ko) 이중특이적 항체 작제물을 포함하는 약제학적 조성물
JP2015519313A5 (OSRAM)
BRPI0406800B1 (pt) Dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
Da Silva et al. Partitioning of glycomacropeptide in aqueous two-phase systems
BR112018007960A2 (pt) conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado.
EP2189471A4 (en) FOXM1 PEPTIDE AND MEDICAMENT THEREFOR
WO2018097603A3 (ko) 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
BR112013022252B1 (pt) método para isolar osteopontina utilizando alimentos concentrados
RU2015126105A (ru) Модифицированные суперспиральные белки с улучшенными свойствами
CN106928320A (zh) 一种合成Etelcalcetide的方法
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
RU2016107873A (ru) Пептиды
JP6603662B2 (ja) タンパク質のチオエーテルコンジュゲーション方法
NZ707895A (en) Formulation for bispecific t-cell engagers (bites)
CN107223133A (zh) 一种可溶的异质二聚t细胞受体及其制法和应用
TW202122410A (zh) 鈣敏感受體激動劑化合物及其應用
KR20110136504A (ko) Rage 수용체 표적 펩타이드에 약물을 결합시킨 것을 특징으로 하는 약물 복합체
BR112012032364B1 (pt) Succinilato de caseína férrica e método para a preparação do mesmo
Shang et al. Membrane reactor for continuous and selective protein mono-PEGylation
CA2794217C (en) Thiosulfonate compound, reversible cationization agent for protein and/or peptide, and method for solubilization
JPWO2017154869A1 (ja) 変異型ヒトエリスロポエチンの製造方法
KR20160074564A (ko) 모발처리제
JP2010006756A (ja) 高分子量セリシン水溶液